Antipsychotic-Treated Schizophrenia Patients Develop Inflammatory and Oxidative Responses Independently From Obesity: However, Metabolic Disturbances Arise From Schizophrenia-Related Obesity

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY

Human Psychopharmacology: Clinical and Experimental Pub Date : 2024-11-07 DOI:10.1002/hup.2913

Sarandol Emre, Sarandol Asli, Mercan Sener, Salih Saygin Eker, Surmen-Gur Esma

{"title":"Antipsychotic-Treated Schizophrenia Patients Develop Inflammatory and Oxidative Responses Independently From Obesity: However, Metabolic Disturbances Arise From Schizophrenia-Related Obesity","authors":"Sarandol Emre, Sarandol Asli, Mercan Sener, Salih Saygin Eker, Surmen-Gur Esma","doi":"10.1002/hup.2913","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To define the impact of obesity on inflammatory and oxidative disturbances in antipsychotic-treated schizophrenia patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Several cytokines, inflammatory, metabolic, and oxidative status markers were evaluated in obese (<i>n</i> = 40) and non-obese (<i>n</i> = 40) antipsychotic-treated patients and compared with age-and BMI-matched controls (<i>n</i> = 80).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Schizophrenia patients had higher leptin, TNF-α, adiponectin, visfatin, resistin, P-selectin, NPY, BDNF, CD40-L, MCP-1, and malondialdehyde, and lower IL-6, ghrelin, neopterin, and vitamin E levels compared to their respective controls (<i>p</i> < 0.001). Total oxidant status was higher in non-obese patients compared to controls (<i>p</i> < 0.001), total antioxidant capacity was higher in obese compared to non-obese patients (<i>p</i> < 0.01), but vitamin A and paraoxonase levels were not different. High sensitive-CRP levels were higher in obsese controls relative to non-obese controls (<i>p</i> < 0.05) and in obese patients relative to non-obese patients (<i>p</i> < 0.001). Fasting glucose, insulin, HbA1c, HOMA-IR, uric acid, total cholesterol, and triglyceride concentrations were higher in obese patients compared to non-obese patients. Insulin concentrations and HOMA-IR were also higher in obese controls than in non-obese controls.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our results suggest that inflammatory responses and oxidative stress develop independently from obesity in antipsychotic-treated schizophrenia patients. However, schizophrenia-induced obesity causes metabolic disturbances; thereby, obese schizophrenia patients are more liable to cardiovascular events and progress of metabolic syndrome than non-obese patients.</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"39 6","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2913","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To define the impact of obesity on inflammatory and oxidative disturbances in antipsychotic-treated schizophrenia patients.

Methods

Several cytokines, inflammatory, metabolic, and oxidative status markers were evaluated in obese (n = 40) and non-obese (n = 40) antipsychotic-treated patients and compared with age-and BMI-matched controls (n = 80).

Results

Schizophrenia patients had higher leptin, TNF-α, adiponectin, visfatin, resistin, P-selectin, NPY, BDNF, CD40-L, MCP-1, and malondialdehyde, and lower IL-6, ghrelin, neopterin, and vitamin E levels compared to their respective controls (p < 0.001). Total oxidant status was higher in non-obese patients compared to controls (p < 0.001), total antioxidant capacity was higher in obese compared to non-obese patients (p < 0.01), but vitamin A and paraoxonase levels were not different. High sensitive-CRP levels were higher in obsese controls relative to non-obese controls (p < 0.05) and in obese patients relative to non-obese patients (p < 0.001). Fasting glucose, insulin, HbA1c, HOMA-IR, uric acid, total cholesterol, and triglyceride concentrations were higher in obese patients compared to non-obese patients. Insulin concentrations and HOMA-IR were also higher in obese controls than in non-obese controls.

Conclusions

Our results suggest that inflammatory responses and oxidative stress develop independently from obesity in antipsychotic-treated schizophrenia patients. However, schizophrenia-induced obesity causes metabolic disturbances; thereby, obese schizophrenia patients are more liable to cardiovascular events and progress of metabolic syndrome than non-obese patients.

查看原文本刊更多论文

经抗精神病药物治疗的精神分裂症患者产生炎症和氧化反应与肥胖无关：然而，与精神分裂症有关的肥胖会导致代谢紊乱。

目的：确定肥胖对接受抗精神病药物治疗的精神分裂症患者的炎症和氧化紊乱的影响：明确肥胖对抗精神病药物治疗的精神分裂症患者炎症和氧化紊乱的影响：方法：评估肥胖（n = 40）和非肥胖（n = 40）抗精神病药物治疗患者的多种细胞因子、炎症、代谢和氧化状态标记物，并与年龄和体重指数匹配的对照组（n = 80）进行比较：结果：与各自的对照组相比，精神分裂症患者的瘦素、TNF-α、脂肪连通素、粘蛋白、抵抗素、P-选择素、NPY、BDNF、CD40-L、MCP-1和丙二醛水平较高，而IL-6、胃泌素、新蝶呤和维生素E水平较低（p 结论：我们的研究结果表明，肥胖患者和非肥胖患者的炎症反应和炎症反应程度与对照组不同：我们的研究结果表明，抗精神病药物治疗的精神分裂症患者的炎症反应和氧化应激与肥胖无关。然而，精神分裂症引起的肥胖会导致代谢紊乱；因此，与非肥胖患者相比，肥胖精神分裂症患者更容易发生心血管事件和代谢综合征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Psychopharmacology: Clinical and Experimental 医学-精神病学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design